Categories AlphaGraphs, Earnings, Finance, LATEST

JPM Earnings: All you need to know about JPMorgan Chase’s Q1 2022 results

Banking giant JPMorgan Chase & Co. (NYSE: JPM) reported lower net profit and revenues for the first quarter of 2022. The bottom line also missed analysts’ estimates. The company’s stock dropped in pre-market trading on Wednesday soon after the announcement, after closing the previous session lower.

JPMorgan Chase Q1 2022 earnings infographic

First-quarter net income dropped sharply to $8.28 billion or $2.63 per share from $14.3 billion or $4.5 per share in the corresponding period of last year. The market was looking for a slightly bigger amount for the latest quarter.

The weak bottom-line performance reflects a 5% decrease in net revenues to $30.7 billion, which also fell short of expectations.


Check this space to read management/analysts’ comments on JPMorgan’s Q1 2022 results


“Our focus this quarter remained on helping our clients navigate difficult markets and unpredictable events, which included working with governments to implement economic sanctions of unprecedented complexity. While our company will continue to deal with this global turmoil, our hearts go out to the extreme suffering of the Ukrainian people and to all of those affected by the war,” said Jamie Dimon, chief executive officer of JP Morgan.

Prior Performance

_________________________________________________________________________________________________________________

Stocks you may like:

Bank of America (BAC) Stock

Wells Fargo (WFC) Stock

JPMorgan Chase (JPM) Stock

Citigroup (C) Stock

Goldman Sachs (GS) Stock

Morgan Stanley (MS) Stock

_________________________________________________________________________________________________________________

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top